We expressed our concern that the Health IT Investment and Standards propose to withdraw or put into containment the standards related to development of the NZePS service. We highlighted that the NZePS solution is only partially implemented across the New Zealand health system and the Ministry is still working with major stakeholders to enable access to NZePS.
29/09/2017. We supported the occupation Pharmacy Technician to remain on the Immediate Skill Shortage List. We also asked for consideration to be given to adding Pharmacists to this list.
15/09/2017. We supported the proposed changes to the warning statements on NSAIDS regarding use in pregnancy. This proposal highlighted the potential risks of taking NSAIDs during pregnancy and we believe the classification of NSAIDs available through general sale should be reviewed.
1/8/2017. We supported the reclassification of fentanyl and the specified precursors from Class B3 to Class B1. This reclassification would improve the search powers of the Police and New Zealand Customs Service to minimise any future fentanyl related illicit activity. We requested that fentanyl has the same exemption as morphine under Regulation 22 of the Misuse of Drugs Regulations 1977, so the proposed change does not impact on pharmacy workflow and patient access.
12/5/2017. This submission was on a ACC proposal to include pharmacists as ACC treatment providers, which will allow pharmacists to be paid directly by ACC for treatment they provide to claimants. We supported this proposal and provided examples of several services community pharmacies could provide to ACC claimants.
24/04/2017. Our submission focused on how community pharmacy provides a vital role in the care of asthma among children and adolescents. While we were pleased to see that pharmacy was referenced twice in this consultation, we made several recommendation on how community pharmacy could be further incorporated into these Guidelines.
28/02/2017. We are supportive of integrated person centric care with a focus on improved health outcomes. Our main concern is the IT infrastructure and funding to enable the framework to be realised. Contractual arrangements need to incentivise collaboration while ensuring that community pharmacies remain separate entities from general practice.
13/02/2017. Our submission covered English communication skills, cultural awareness, rural workforce, and having a greater focus on business skills, patient-centric service provision and experiential learning in the curriculum.
26/01/2017. We supported the proposed changes to the postgraduate certificate in clinical pharmacy degree. We believe these proposed changes will help meet the current and future needs of the profession.
The Guild pledges its support for updating the strategy. We highlight the important contribution community pharmacy makes in helping older people to take charge of their own health care management, and argue for more resources to expand and enhance this important role.
The Guild received an overwhelming number of feedback responses from our members. The key message we received is clear; without any additional funding from DHBs, no solution will address the margin issue.
We are very pleased that the Ministry of Health has recognised the value that pharmacists can provide to the health sector as a whole.
In our submission, we set out our support for an expanded role for pharmacists as members of the multidisciplinary healthcare team, enhancing pharmacy services in the community, and community pharmacy’s role in the systemised delivery of health promotion and personal health messages.
We were pleased to see that pharmacists were acknowledged throughout the document and this emphasised their importance in the primary healthcare team and their ability to contribute to the healthy outcomes for patients with respiratory conditions. This document presents many opportunities for community pharmacy to contribute to achieving the best possible health outcomes for people with respiratory conditions. We welcomed the opportunity to work collaboratively with other national pharmacy organisations to develop specific services for respiratory conditions that can be provided through community pharmacy.
We stated that we were unable to support this code while there remains no explicit process to ensure recognition of the huge input required at community pharmacy level to ensure patient safety during a consumer-level recall. We looked forward to supporting the Recall code when a clear process for consumer-level recalls, including the reimbursement of direct costs incurred by community pharmacy, is included.
Overall, pharmacists expressed support for the Stage Four funding model. It should be noted that some issues raised previously continue to remain unaddressed.